Company Profile · Healthcare

Aier Eye Hospital Group

300015 · Shenzhen
Industry
Hospital Operations
Exchange
Shenzhen
Country
China
IPO date
Oct 30, 2009
Employees
42,817
Website
www.aierchina.com
Price at Publication
¥8.71
Aug 15, 2026 close
Fair Buy
≤ ¥5.5
Margin-of-safety entry
Baillie Growth Score
43/100
Weak
Buffett Score
86/100
Elite
Intrinsic Value · Three-Tier Range Price at publication ¥8.71 · Within the fair intrinsic-value range

Composite valuation range · conservative ¥5–¥5.5 / fair ¥8–¥11 / optimistic ¥15.5–¥17. At the publication price of ¥8.71 (Aug 15, 2026), Within the fair intrinsic-value range.

Financial snapshot
Market capCN¥74.21B
Revenue (TTM)CN¥22.79B
EBITDACN¥5.77B
Profit margin11.17%
ROE11.78%
P/E (TTM)29.56
Forward P/E41.84
PEG1.65
EPSCN¥0.27
Dividend yield1.27%
52-week rangeCN¥7.73 – CN¥12.60

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

About the company

Aier Eye Hospital Group Co., Ltd. operates as an ophthalmic medical company in China, Hong Kong, Europe, the United States, Europe, and Southeast Asia. It offers diagnosis and treatment of various ophthalmic diseases, surgical services, medical optometry, and lens fitting for fundus diseases, glaucoma, and cataract. The company also provides training courses for cataract cases, ICL surgery, and presbyopia surgery. Aier Eye Hospital Group Co., Ltd. was founded in 2002 and is headquartered in Changsha, China

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

Research on this stock
43/100 Hold Aier Eye Hospital: Net Goodwill Equals 43% of Book Equity, Adjusted Profit Grew 1.36% in 2025, and CNY8.71 Leaves No Conservative Margin of Safety Aier Eye Hospital is China's largest listed ophthalmology network, combining consumer-paid refractive and optometry services with insured treatment and an acquisition-fund system that incubates hospitals before consolidating them. FY2025 revenue rose 6.53% to CNY22.353bn, but adjusted attributable profit grew only 1.36%, net goodwill of CNY9.486bn equals roughly 43% of attributable equity, and estimated domestic organic growth runs in the low- to mid-single digits. Rating Hold: at CNY8.71 the shares sit inside the CNY8.0-11.0 acceptable-hold range but 24%-34% above the CNY6.5-7.0 conservative intrinsic value, leaving no margin of safety. Aier Eye Hospital Group Co., Ltd.300015 · ShenzhenHospital OperationsAug 15, 2026